Literature DB >> 15448994

Efficacy of routine follow-up after first-line treatment for testicular cancer.

J R Spermon1, J A Witjes, L A L M Kiemeney.   

Abstract

To define guidelines for the follow-up management of patients treated for testicular germ cell tumor this study assessed characteristics of patients with recurrent disease. The charts of 505 patients with testicular cancer treated and followed-up at the University Medical Centre Nijmegen between 1982-2000 were reviewed retrospectively. In 42 patients disease recurrence was found during routine follow-up. In a subset of patients no recurrences were seen after first-line treatment: (a) pathological stage IIa nonseminoma patients who were adjuvantly treated with chemotherapy and (b) histologically confirmed complete responders after primary chemotherapy. Furthermore, in low-stage disease no intra-abdominal recurrences were seen in (a) pathological stage I nonseminoma patients and (b) low-stage seminoma patients who received radiotherapy. The risk of recurrent testicular cancer depends on primary therapy and efficacy of it; these results indicate a limited role for follow-up in pathological stage II nonseminoma patients adjuvantly treated with chemotherapy and in histologically confirmed complete responders after chemotherapy. Abdominal computed tomography does not appear necessary in routine follow-up of patients treated for low-stage testicular cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15448994     DOI: 10.1007/s00345-004-0441-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  31 in total

Review 1.  Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM).

Authors:  S Krege; R Souchon; H J Schmoll
Journal:  Eur Urol       Date:  2001-10       Impact factor: 20.096

Review 2.  Is biopsy of the contralateral testis necessary in patients with germ cell tumors?

Authors:  H W Herr; J Sheinfeld
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

3.  Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer--a necessary risk?

Authors:  M L Harvey; T R Geldart; R Duell; G M Mead; K Tung
Journal:  Ann Oncol       Date:  2002-02       Impact factor: 32.976

Review 4.  Surgery versus surveillance in stage I non-seminoma testicular cancer.

Authors:  D J Sonneveld; H S Koops; D T Sleijfer; H J Hoekstra
Journal:  Semin Surg Oncol       Date:  1999-12

5.  Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.

Authors:  A Hollender; E A Stenwig; S Ous; S D Fosså
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

6.  Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections.

Authors:  E P Fox; T D Weathers; S D Williams; P J Loehrer; T M Ulbright; J P Donohue; L H Einhorn
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

7.  Efficacy of radiographic chest imaging in patients with testicular cancer.

Authors:  E B Fernandez; E Colon; D G McLeod; J W Moul
Journal:  Urology       Date:  1994-08       Impact factor: 2.649

Review 8.  Late relapse of germ cell tumors after cisplatin-based chemotherapy.

Authors:  A Gerl; C Clemm; N Schmeller; M Hentrich; R Lamerz; W Wilmanns
Journal:  Ann Oncol       Date:  1997-01       Impact factor: 32.976

9.  Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years.

Authors:  J W Moul; D F Paulson; R K Dodge; P J Walther
Journal:  J Urol       Date:  1990-03       Impact factor: 7.450

10.  Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.

Authors:  M J Seckl; G J Rustin; K D Bagshawe
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more
  3 in total

Review 1.  [Follow-up of testicular germ cell tumors-historical aspects and current recommendations].

Authors:  Klaus-Peter Dieckmann; Christian Guido Ruf; Raphael Gübitz; Christian Wülfing; Friedemann Zengerling
Journal:  Urologe A       Date:  2022-04-06       Impact factor: 0.639

2.  What is the value of routine follow-up in stage I seminoma after paraaortic radiotherapy?: an analysis of the German Testicular Cancer Study Group (GTCSG) in 675 prospectively followed patients.

Authors:  Johannes Clasen; Heinz Schmidberger; Rainer Souchon; Lothar Weissbach; Michael Hartmann; Jörg T Hartmann; Thomas Hehr; Michael Bamberg
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

3.  Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis.

Authors:  Johannes Classen; Rainer Souchon; Thomas Hehr; Michael Hartmann; Jörg T Hartmann; Michael Bamberg
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-14       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.